Trial: 201911028

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose
Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients < or = 70 years old with Untreated Mantle Cell Lymphoma

Phase

II

Principal Investigator

Kahl, Brad

Disease Site

Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov